$298.90
-2.65
(-0.88%)
As of Sep 5, 2026, 10:33 AM EDT · cached
Price history
Novo Nordisk (NOVO-B) is trading down at $298.90 (-0.88%) on Europe, as of the latest quote. It is a Europe constituent in the Health Care sector.
About Novo Nordisk
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
Recent News (20)
-
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 31 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of …
-
David Lozano Wins King of the Mountains at the Philadelphia Cycling Classic Spaniard living with type 1 diabetes takes the climber's jersey as America's biggest one-day race returns after a decade away PHILADELPHIA, Aug. 30, 2026 /PRNewswire/ -- David Lozano (ESP) of Team Nov…
-
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren’t the Reason
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren’t the Reason
-
Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip
-
Why is Novo Nordisk stock sliding today?
Why is Novo Nordisk stock sliding today?
-
Ozempic maker Novo Nordisk downgraded to sell following 70% stock-price dive from peak Ozempic maker Novo Nordisk downgraded to sell following 70% stock-price dive from peak MarketWatch
-
Ozempic maker Novo Nordisk downgraded to sell following 70% stock-price dive from peak While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
-
JPMorgan raises Novo Nordisk stock price target on Ozempic outlook JPMorgan raises Novo Nordisk stock price target on Ozempic outlook Investing.com
-
Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars
Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars
-
Is the Weight-Loss Drug Market Really a Winner-Take-All Fight Between Novo Nordisk (NVO) and Eli Lilly (LLY)?
Is the Weight-Loss Drug Market Really a Winner-Take-All Fight Between Novo Nordisk (NVO) and Eli Lilly (LLY)?
-
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of …
-
Lexicon earns $10M milestone from Novo Nordisk for obesity drug
Lexicon earns $10M milestone from Novo Nordisk for obesity drug
-
-
Novo Nordisk Expands Its AI Push With AWS, But Can It Accelerate Drug Discovery?
Novo Nordisk Expands Its AI Push With AWS, But Can It Accelerate Drug Discovery?
-
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
-
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start
Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start
-
-
-
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More
-
Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?
More Health Care stocks
- BMY Bristol Myers Squibb
- JNJ Johnson & Johnson
- LLY Lilly (Eli)
- MRK Merck & Co.
- PFE Pfizer
- VTRS Viatris
- ZTS Zoetis
- A Agilent Technologies